



**Alex Derchak, Ph.D., Joins VivoMetrics®**

*Cardiopulmonary Physiologist Enhances Company's Clinical Research Department*

Ventura, CA, December 03, 2003 -- VivoAlex Derchak, Ph.D. has joined VivoMetrics as director of clinical research. In this capacity, he will help develop protocols for the use of LifeShirt® in clinical trials with a wide range of endpoints in various disease states.

Prior to joining VivoMetrics, Derchak was a senior scientific communications associate in the global scientific information and communications at Eli Lilly. Derchak was responsible for coordinating the analysis and communication of clinical data related to a first in class, life-saving molecule. In addition, he employed his research background in cardiopulmonary physiology, leading writing teams in the analysis and communication of clinical and pre-clinical trial data.

"Dr. Derchak's underlying understanding of the clinical trials process and the pharmaceutical industry will help us attain our goal of speeding clinical trials through better and more accurate scientific data," said Paul Kennedy, president and CEO, VivoMetrics. "We hope to leverage his experience in the arena of cardiopulmonary physiology to develop and validate new clinical endpoints – including the expansion of our cough measurement."

Derchak earned his pre-medical bachelor of science degree from the University of Notre Dame in Notre Dame, Ind.; his masters of science in Exercise Physiology from the School of Health, Physical Education and Recreation at Indiana University, Bloomington, Ind.; and his doctorate in Human Performance/Exercise Physiology from the School of Graduate Studies at Indiana University.

"VivoMetrics possesses all of the attributes I look for in a new venture — a prestigious Scientific Advisory Board and an opportunity to align with a company committed to impacting the pharmaceutical industry," said Dr. Derchak. "The LifeShirt System is changing how clinical trials are being conducted today. I look forward to collaborating with my new colleagues regarding new initiatives to leverage the LifeShirt System into its next phase."

"I'm impressed by the 21 CFR Part 11 infrastructure that VivoMetrics has built from the ground up," he added. "We have excellent quality systems in place here, and management is dedicated to maintaining this level of quality in everything they do."

"The LifeShirt provides tremendous financial and safety benefits to pharmaceutical companies," he stated. "Financially, the pharmaceutical industry is under intense pressure to deliver drugs to market price at lower cost. At the same time, they have an obligation to their shareholders to try to provide as much return on investment as possible. The LifeShirt can help reduce costs and expedite time from discovery to launch of new molecules.

"Also, the pharmaceutical industry is under ever increasing pressure to ensure the products they develop are safe," he concluded. "Having the ability to monitor clinical trial subjects continuously throughout their daily activities will lead to a more applicable understanding of the safety profile of new products."

Stacey Williams  
Director of Marketing  
VivoMetrics Inc.  
805.275.5864  
[swilliams@vivometrics.com](mailto:swilliams@vivometrics.com)

Aimee Corso  
WeissComm Partners  
for VivoMetrics  
310.780.2661  
[acorso@weisscommpartners.com](mailto:acorso@weisscommpartners.com)